10x Genomics (TXG) Other Accumulated Expenses (2018 - 2026)

10x Genomics (TXG) has 9 years of Other Accumulated Expenses data on file, last reported at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 31.42% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.4 million (down 31.42% YoY), and the FY2025 full-year result was $11.0 million, up 99.51% from the prior year.
• Other Accumulated Expenses retreated to $8.4 million in Q1 2026, from $11.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $12.8 million in Q2 2025 to a low of $3.3 million in Q2 2023.
• A 5-year average of $7.2 million and a median of $5.7 million in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 2398.98% in 2022 and slumped 34.2% in 2023, its largest moves.
• Tracing TXG's Other Accumulated Expenses over 5 years: stood at $6.7 million in 2022, then slumped by 34.2% to $4.4 million in 2023, then gained by 24.88% to $5.5 million in 2024, then soared by 99.51% to $11.0 million in 2025, then declined by 23.28% to $8.4 million in 2026.
• Business Quant data shows TXG's Other Accumulated Expenses at $8.4 million in Q1 2026, $11.0 million in Q4 2025, and $12.4 million in Q3 2025.